These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 21326118)

  • 1. Undetectable antimüllerian hormone levels and recovery of chemotherapy-induced ovarian failure in women with breast cancer on an oral aromatase inhibitor.
    Dieudonné AS; Vandenberghe J; Geerts I; Billen J; Paridaens R; Wildiers H; Neven P
    Menopause; 2011 Jul; 18(7):821-4. PubMed ID: 21326118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrine-responsive early breast cancer.
    Torino F; Barnabei A; De Vecchis L; Appetecchia M; Strigari L; Corsello SM
    Endocr Relat Cancer; 2012 Apr; 19(2):R21-33. PubMed ID: 22241718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer.
    Torino F; Barnabei A; De Vecchis L; Sini V; Schittulli F; Marchetti P; Corsello SM
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):27-42. PubMed ID: 23953684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay.
    Decanter C; Peigne M; Mailliez A; Morschhauser F; Dassonneville A; Dewailly D; Pigny P
    Fertil Steril; 2014 Aug; 102(2):483-7. PubMed ID: 24951363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer.
    Partridge AH; Ruddy KJ; Gelber S; Schapira L; Abusief M; Meyer M; Ginsburg E
    Fertil Steril; 2010 Jul; 94(2):638-44. PubMed ID: 19409543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane.
    Guerrero A; Gavilá J; Folkerd E; Ortiz B; Martínez F; García A; Climent MA; Guillem V; Ruíz A
    Ann Oncol; 2013 Mar; 24(3):674-9. PubMed ID: 23108951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel.
    Ortmann O; Pagani O; Jones A; Maass N; Noss D; Rugo H; van de Velde C; Aapro M; Coleman R
    Cancer Treat Rev; 2011 Apr; 37(2):97-104. PubMed ID: 20594763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amenorrhea following chemotherapy for breast cancer: effect on disease-free survival.
    Collichio F; Pandya K
    Oncology (Williston Park); 1994 Dec; 8(12):45-52. PubMed ID: 7888312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum follicle stimulating hormone (FSH) levels.
    Panidis D; Katsikis I; Karkanaki A; Piouka A; Armeni AK; Georgopoulos NA
    Med Hypotheses; 2011 Oct; 77(4):649-53. PubMed ID: 21807466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of anti-Müllerian hormone in the diagnosis and prediction of loss of ovarian function following chemotherapy for early breast cancer.
    Anderson RA; Mansi J; Coleman RE; Adamson DJA; Leonard RCF
    Eur J Cancer; 2017 Dec; 87():58-64. PubMed ID: 29117576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian cysts during tamoxifen use may affect the prognostic markers of premenopausal breast cancer.
    Han W; Kim H; Ku SY; Kim SH; Choi YM; Kim JG; Moon SY
    Gynecol Endocrinol; 2013 Jan; 29(1):16-9. PubMed ID: 22812679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian function and childbearing issues in breast cancer survivors.
    Gadducci A; Cosio S; Genazzani AR
    Gynecol Endocrinol; 2007 Nov; 23(11):625-31. PubMed ID: 17926162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients.
    Bozza C; Puglisi F; Lambertini M; Osa EO; Manno M; Del Mastro L
    Endocr Relat Cancer; 2014 Feb; 21(1):R51-65. PubMed ID: 24292601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Observation and clinical significance of adjuvant chemotherapy-induced amenorrhea in premenopausal breast cancer patients].
    Li HP; Ma LW; Zhang SL; Jia TZ; Deng HJ; Zhang ZH; Liang L; Wang MP; Xiao Y; Cao BS; Chen S; Wang YF
    Zhonghua Zhong Liu Za Zhi; 2006 Nov; 28(11):848-51. PubMed ID: 17416008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
    El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
    Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of recovery of ovarian function during aromatase inhibitor therapy.
    Henry NL; Xia R; Banerjee M; Gersch C; McConnell D; Giacherio D; Schott AF; Pearlman M; Stearns V; Partridge AH; Hayes DF
    Ann Oncol; 2013 Aug; 24(8):2011-6. PubMed ID: 23613476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormone therapy in breast cancer: the end of tamoxifen?].
    Delozier T
    Bull Cancer; 2005 Feb; 92(2):142-50. PubMed ID: 15749643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause.
    La Marca A; De Leo V; Giulini S; Orvieto R; Malmusi S; Giannella L; Volpe A
    J Soc Gynecol Investig; 2005 Oct; 12(7):545-8. PubMed ID: 16046154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.